Our pipeline focuses on novel small molecule kinase inhibitors targeting malignant cells both directly and through modulation of the tumor microenvironment. Verastem Oncology programs include:

    • Phosphoinositide 3-kinase (PI3K) delta and gamma
    • Focal adhesion kinase (FAK)
    • RAF/MEK


PI3K Delta Gamma Inhibitor


Pipeline Verastem Oncology



FAK Inhibitor 

Verastem Pipeline FAK January 2020

These studies are investigating treatments or outcomes that have not received approval from a Health Authority. There is no guarantee that the outcome of these studies will result in approval.